Recently, Dingdang Health Technology Group Co., Ltd. ("Dingdang Health", stock code: 09886.HK) completed its initial public offering and listing on the Hong Kong Stock Exchange. Dingdang Health is expected to issue 33,537,000 shares this time, including 3,354,000 shares in Hong Kong public offering, 30,183,000 shares in international offering, and 5,030,500 over-allotment shares.
Dingdang Health was established in 2014. As a leader in providing fast digital medical services in China, Dingdang Health has been committed to promoting the innovation and upgrading of China's medical industry by creating online-to-offline solutions-led instant drug retailing and medical consultation.
CICC and CMBI acted as joint sponsors and joint global coordinators, Futu Securities acted as joint bookrunners and joint lead managers, and Silverbricks Securities acted as joint lead managers.
Deloitte provided audit services.
Jingtian & Gongcheng and Clifford Chance acted as the issuer's PRC legal advisors and Hong Kong legal advisors respectively.
CM Law Firm and Paul Hastings LLP acted as the joint sponsor’s PRC lawyer and Hong Kong lawyer respectively.
Maples and Calde LLP acted as Cayman Islands legal counsel.
Frost & Sullivan acted as an independent industry consultant.